Literature DB >> 30903577

An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report.

Masatsugu Hiraki1, Toshiya Tanaka2, Futa Koga3, Akimasa Saito4, Noriko Oza3, Osamu Ikeda2, Tatsuya Manabe5, Atsushi Miyoshi2, Kenji Kitahara2, Seiji Sato2, Hirokazu Noshiro5.   

Abstract

Entities:  

Year:  2020        PMID： 30903577     DOI： 10.1007/s12029-019-00228-7

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  20 in total

1.  Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study.

Authors:  M González-Barón; J Feliu; I de la Gándara; E Espinosa; A Colmenarejo; B Martínez-Martínez; E Blanco; C García-Girón; F Juárez; P Garrido
Journal:  Eur J Cancer       Date:  1995-12       Impact factor: 9.162

2.  Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.

Authors:  Yasuhiro Shimada; Tetsuya Hamaguchi; Junki Mizusawa; Norio Saito; Yukihide Kanemitsu; Nobuhiro Takiguchi; Masayuki Ohue; Takeshi Kato; Yasumasa Takii; Toshihiko Sato; Naohiro Tomita; Shigeki Yamaguchi; Makoto Akaike; Hideyuki Mishima; Yoshiro Kubo; Kenichi Nakamura; Haruhiko Fukuda; Yoshihiro Moriya
Journal:  Eur J Cancer       Date:  2014-06-20       Impact factor: 9.162

3.  ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury.

Authors:  Naga P Chalasani; Paul H Hayashi; Herbert L Bonkovsky; Victor J Navarro; William M Lee; Robert J Fontana
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

4.  Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

Authors:  Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Oncologic Outcomes of Oral Adjuvant Chemotherapy Regimens in Stage III Colon Cancer: Tegafur-Uracil Plus Leucovorin Versus Capecitabine.

Authors:  Jo Tashiro; Shigeki Yamaguchi; Toshimasa Ishii; Hiroka Kondo; Kiyoka Hara; Hiroki Shimizu; Kenichi Takemoto; Asami Suzuki
Journal:  Clin Colorectal Cancer       Date:  2017-01-25       Impact factor: 4.481

Review 6.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

7.  A case of allergic liver injury induced by tegafur.

Authors:  M Baba; T Shima; T Tanaka; M Nakayabu; H Hasegawa; S Suzuki; I Kusano
Journal:  J Gastroenterol       Date:  1994-02       Impact factor: 7.527

8.  Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.

Authors:  K Shirao; P M Hoff; A Ohtsu; P J Loehrer; I Hyodo; S Wadler; R G Wadleigh; P J O'Dwyer; K Muro; Y Yamada; N Boku; F Nagashima; J L Abbruzzese
Journal:  J Clin Oncol       Date:  2004-07-26       Impact factor: 44.544

9.  Chronic active hepatitis and liver cirrhosis in association with combined tamoxifen/tegafur adjuvant therapy.

Authors:  S Maruyama; C Hirayama; J Abe; J Tanaka; K Matsui
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

10.  Safety analysis of two different regimens of uracil-tegafur plus leucovorin as adjuvant chemotherapy for high-risk stage II and III colon cancer in a phase III trial comparing 6 with 18 months of treatment: JFMC33-0502 trial.

Authors:  Takashi Tsuchiya; Sotaro Sadahiro; Kazuaki Sasaki; Ken Kondo; Kenji Katsumata; Genichi Nishimura; Yoshihiro Kakeji; Hideo Baba; Takayuki Morita; Keiji Koda; Seiji Sato; Junji Matsuoka; Yoshiyuki Yamaguchi; Hisashi Usuki; Chikuma Hamada; Susumu Kodaira; Shigetoyo Saji
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-18       Impact factor: 3.333
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.